CD30 in Cutaneous Pathology

Angel Fernandez-Flores; David Cassarino

doi:10.1097/DAD.0000000000002422

CD30 in Cutaneous Pathology

Am J Dermatopathol. 2023 Sep 1;45(9):593-607. doi: 10.1097/DAD.0000000000002422.

Authors

Angel Fernandez-Flores^{1

2

3}, David Cassarino⁴

Affiliations

¹ Dermatopathologist, Department of Histopathology, University Hospital El Bierzo, Ponferrada, Spain.
² Department of Cellular Pathology, Hospital de la Reina, Ponferrada, Spain.
³ Research Department, Institute for Biomedical Research of a Coruña (INIBIC), University of a Coruña (UDC), A Coruña, Spain; and.
⁴ Pathologist, Los Angeles Medical Center (LAMC), Southern California Kaiser Permanente, Departments of Pathology and Dermatology, Los Angeles, CA.

PMID: 37625801
DOI: 10.1097/DAD.0000000000002422

Abstract

The discovery of CD30 as a diagnostic marker was essential in the identification of not only some lymphomas but also many other solid tumors and benign reactive conditions. Many CD30+ cutaneous disorders and tumors have been categorized since the identification of the marker. With the design of targeted therapies against CD30+ tumoral cells, the interest in CD30 determination was not only diagnostic but also mainly therapeutic. In this article, we explore the historical aspects of the discovery of CD30 and examine the main CD30-related cutaneous pathology, susceptible of anti-CD30 modern treatments.